Therefore, with the data presented in our study and previous articles in the literature, we believe that PSA screening has crucial impacts on functional and oncological results, and urologists and primary care doctors should maintain the screening with PSA and DRE in order to optimize outcomes in patients with prostate cancer. Here, KLK3 is linked to prostate carcinoma.